Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pacira Pharm Inc
(NQ:
PCRX
)
30.72
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pacira Pharm Inc
< Previous
1
2
3
Next >
Earnings Preview For Pacira BioSciences
February 27, 2023
Via
Benzinga
Where Pacira BioSciences Stands With Analysts
January 31, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
January 23, 2023
On Monday, 12 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
January 10, 2023
Tuesday's session saw 16 companies set new 52-week lows.
Via
Benzinga
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday
December 13, 2022
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Pacira BioSciences's Return On Capital Employed Insights
November 23, 2022
Via
Benzinga
Pacira Touts Positive Data From EXPAREL Study In Toe Correction Surgery
September 21, 2022
Via
Benzinga
Pacira Posts Topline Data From Knee Surgery Study With Its Flagship Pain Management Drug
September 07, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
December 13, 2022
On Tuesday, 49 companies hit new 52-week lows.
Via
Benzinga
Pacira BioSciences: Q3 Earnings Insights
November 03, 2022
Pacira BioSciences (NASDAQ:PCRX) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Pacira Pharmaceuticals Stock Shows Rising Relative Strength
October 07, 2022
On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73.
Via
Investor's Business Daily
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
September 07, 2022
Via
Benzinga
Pacira BioSciences' Return On Capital Employed Overview
August 08, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
November 16, 2022
On Wednesday, 70 companies set new 52-week lows.
Via
Benzinga
Pacira BioSciences: Q2 Earnings Insights
August 03, 2022
Pacira BioSciences (NASDAQ:PCRX) reported its Q2 earnings results on Wednesday, August 3, 2022. Here's what investors need to know about the announcement.
Via
Benzinga
Needham Maintains Buy Rating for Pacira BioSciences: Here's What You Need To Know
June 15, 2022
Needham has decided to maintain its Buy rating of Pacira BioSciences (NASDAQ:PCRX) and lower its price target from $84.00 to $76.00. Shares of Pacira BioSciences are trading up 3.85% over the last 24...
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
June 15, 2022
Jefferies raised Tapestry, Inc. (NYSE: TPR) price target from $30 to $45. Tapestry shares rose 2.2% to close at $31.60 on Tuesday.
Via
Benzinga
Pacira Pharmaceuticals Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark
June 08, 2022
On Wednesday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 66 to 75.
Via
Investor's Business Daily
Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82
June 08, 2022
Looking for the best stocks to buy? Focus on those with rising relative price strength, such as Regeneron Pharmaceutical stock.
Via
Investor's Business Daily
Vertex Pharmaceuticals Receives Composite Rating Upgrade
May 24, 2022
The IBD SmartSelect Composite Rating for VRTX stock increased from 94 to 96 Tuesday, a sign of strong fundamentals.
Via
Investor's Business Daily
Pacira BioSciences's Return on Invested Capital Overview
May 20, 2022
Pulled from Benzinga Pro data, Pacira BioSciences (NASDAQ:PCRX) posted Q1 earnings of $6.83 million, an increase from Q4 of 233.1%. Sales dropped to $157.99 million, a 0.76% decrease between quarters.
Via
Benzinga
Gilead Stock Earns Rating Upgrade After Quick Turnaround
May 19, 2022
A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Pacira BioSciences: Q1 Earnings Insights
May 04, 2022
Pacira BioSciences (NASDAQ:PCRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Pacira BioSciences Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 28, 2022
Pacira BioSciences (NASDAQ:PCRX) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
April 14, 2022
On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago.
Via
Investor's Business Daily
28 Biggest Movers From Yesterday
April 12, 2022
Gainers SailPoint Technologies Holdings, Inc. (NYSE: SAIL) shares jumped 29.16% to close at $64.05 on Monday after private equity firm Thoma Bravo announced plans to acquire...
Via
Benzinga
Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92
April 07, 2022
On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92.
Via
Investor's Business Daily
Stocks That Hit 52-Week Highs On Thursday
April 07, 2022
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...
Via
Benzinga
Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90
April 06, 2022
On Wednesday, Biohaven Pharma Holdings stock had its Relative Strength (RS) Rating upgraded to 92 from 86 a day ago.
Via
Investor's Business Daily
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
April 04, 2022
Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91.
Via
Investor's Business Daily
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.